Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme
Authors:
- Federica PoggialiniFederica Poggialini
- Chiara VagagginiCVChiara Vagaggini
- Annalaura BraiAnnalaura Brai
- Claudia PasqualiniClaudia Pasqualini
- Emmanuele CrespanECEmmanuele Crespan
- Giovanni MagaGiovanni Maga
- Cecilia PeriniCPCecilia Perini
- Noemi CabellaNCNoemi Cabella
- Lorenzo BottaLBLorenzo Botta
- Francesca MusumeciFrancesca Musumeci
- Maria FrosiniMFMaria Frosini
- Silvia SchenoneSilvia Schenone
Open Access
- 30 January 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 453
Abstract
The therapeutic use of tyrosine kinase inhibitors (TKIs) represents one of the successful strategies for the treatment of glioblastoma (GBM). Pyrazolo[3,4-d]pyrimidines have already been reported as promising small molecules active as c-Src/Abl dual inhibitors. Herein, we present a series of pyrazolo[3,4-d]pyrimidine derivatives, selected from our in-house library, to identify a promising candidate active against GBM. The inhibitory activity against c-Src and Abl was investigated, and the antiproliferative profile against four GBM cell lines was studied. For the most active compounds endowed with antiproliferative efficacy in the low-micromolar range, the effects toward nontumoral, healthy cell lines (fibroblasts FIBRO 2-93 and keratinocytes HaCaT) was investigated. Lastly, the in silico and in vitro ADME properties of all compounds were also assessed. Among the tested compounds, the promising inhibitory activity against c-Src and Abl (Ki 3.14 µM and 0.44 µM, respectively), the irreversible, apoptotic-mediated death toward U-87, LN18, LN229, and DBTRG GBM cell lines (IC50 6.8 µM, 10.8 µM, 6.9 µM, and 8.5 µM, respectively), the significant reduction in GBM cell migration, the safe profile toward FIBRO 2-93 and HaCaT healthy cell lines (CC50 91.7 µM and 126.5 µM, respectively), the high metabolic stability, and the excellent passive permeability across gastrointestinal and blood–brain barriers led us to select compound 5 for further in vivo assays.Keywords
Funding Information
- Regione Toscana (TUSCAVIR.NET Bando Ricerca Salute 2018 B64I18013740002, Grant IG-2019, project code 23725, Grant IG-2017, project code 20762, Grant IG-2020, project code 24448, PRIN 2017 2017SA5837_004)
- the AIRC Foundation for Cancer Research in Italy (Fondazione AIRC per la Ricerca sul Cancro, AIRC) (TUSCAVIR.NET Bando Ricerca Salute 2018 B64I18013740002, Grant IG-2019, project code 23725, Grant IG-2017, project code 20762, Grant IG-2020, project code 24448, PRIN 2017 2017SA5837_004)
- Ministero dell’Istruzione, dell’Università e della Ricerca (TUSCAVIR.NET Bando Ricerca Salute 2018 B64I18013740002, Grant IG-2019, project code 23725, Grant IG-2017, project code 20762, Grant IG-2020, project code 24448, PRIN 2017 2017SA5837_004)
This publication has 37 references indexed in Scilit:
- Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cellsBioorganic & Medicinal Chemistry Letters, 2011
- Design, Synthesis, Biological Activity, and ADME Properties of Pyrazolo[3,4-d]pyrimidines Active in Hypoxic Human Leukemia Cells: A Lead Optimization StudyJournal of Medicinal Chemistry, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitorsEuropean Journal of Medicinal Chemistry, 2010
- Structure-Based Optimization of Pyrazolo[3,4-d]pyrimidines as Abl Inhibitors and Antiproliferative Agents toward Human Leukemia Cell LinesJournal of Medicinal Chemistry, 2008
- Antiproliferative and proapoptotic activities of new pyrazolo[3,4‐ d ]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cellsThe FASEB Journal, 2008
- Targeting the Cell Cycle: A New Approach to Cancer TherapyJournal of Clinical Oncology, 2005
- Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell lineEuropean Journal of Medicinal Chemistry, 2004
- Synthesis of 1-(2-chloro-2-phenylethyl)-6-methylthio-1H-pyrazolo[3,4-d]pyrimidines 4-amino substituted and their biological evaluationEuropean Journal of Medicinal Chemistry, 2004
- Cell-cycle dysregulation and anticancer therapyTrends in Pharmacological Sciences, 2003